Molecular and functional characterization of a natural homozygous Arg67His mutation in the prothrombin gene of a patient with a severe procoagulant defect contrasting with a mild hemorrhagic phenotype

Sepideh Akhavan, Raimondo De Cristofaro, Flora Peyvandi, Silvia Lavoretano, Raffaele Landolfi, and Pier M. Mannucci

In a patient who presented with a severe coagulation deficiency in plasma contrasting with a very mild hemorrhagic diathesis a homozygous Arg67His mutation was identified in the prothrombin gene. Wild-type (factor IIa [FIIa]-WT) and mutant Arg67His thrombin (FIIa-MT67) had similar amidolytic activity. By contrast, the kcat/Km value of fibrinopeptide A hydrolysis by FIIa-WT and FIIa-MT67 was equal to 2.1 × 10^7 M⁻¹s⁻¹ and 9 × 10^5 M⁻¹s⁻¹. Decreased activation of protein C (PC) correlated with the 33-fold decreased binding affinity for thrombomodulin (TM; Kd = 65.3 nM vs 2.1 nM, in FIIa-MT67 and in FIIa-WT, respectively). In contrast, hydrolysis of PC in the absence of TM was normal. The Arg67His mutation had a dramatic effect on the cleavage of protease-activated G protein-coupled receptor 1 (PAR-1) 38-60 peptide (kcat/Km = 4 × 10^7 M⁻¹s⁻¹ to 1.2 × 10^6 M⁻¹s⁻¹). FIIa-MT67 showed a weaker platelet activating capacity, attributed to a defective PAR-1 interaction, whereas the interaction with glycoprotein Ib was normal. A drastic decrease (up to 500-fold) of the second-order rate constant pertaining to heparin cofactor II (HCII) interaction, especially in the presence of dermatan sulfate, was found for the FIIa-MT67 compared with FIIa-WT, suggesting a severe impairment of thrombin inhibition by HCII in vivo. Finally, the Arg67His mutation was associated with a 5-fold decrease of prothrombin activation by the factor Xa-factor Va complex, perhaps through impairment of the prothrombin-factor Va interaction. These experiments show that the Arg67His substitution affects drastically both the procoagulant and the anticoagulant functions of thrombin as well as its inhibition by HCII. The mild hemorrhagic phenotype might be explained by abnormalities that ultimately counterbalance each other.

© 2002 by The American Society of Hematology
Patient, materials, and methods

Patient

At the age of 1 year an Iranian girl, born from a consanguineous marriage, developed a buttock hematoma following a fall from a chair. Even though the hematoma was minor and needed no specific treatment, it was judged disproportionate to the trauma by her pediatrician and led to the laboratory evaluation of coagulation. A prolongation of both the prothrombin time (79 seconds; normal, 12-14 seconds) and of the activated partial thromboplastin time (102 seconds; normal, 30-40 seconds) was found with undetectable levels of prothrombin functional activity (< 1%). Since then the girl, who is now 11 years old, has had no spontaneous or posttraumatic bleeding symptoms, with the exception of sporadic bruising after minor traumas. She now 11 years old, has had no spontaneous or posttraumatic bleeding symptoms, with the exception of sporadic bruising after minor traumas. She has had no surgical operations, and the loss of deciduous teeth was uneventful. The parents, who are first cousins, are asymptomatic and have approximately half-normal levels of prothrombin activity (59% and 69%) contrasting with normal levels of prothrombin antigen (103% and 121%). Other relatives are asymptomatic but were not investigated.

Coagulation assays

The level of prothrombin antigen was measured in plasma by quantitative Laurell electroimmunoassay and enzyme-linked immunosorbent assay (ELISA) using a polyclonal antihuman prothrombin rabbit antiserum (Asera II; Diagnostics Stage, Asnieres, France). Thrombin coagulant activity was measured by a 1-stage assay, using Taipan snake venom (Diagnostic Reagents, Thame, Oxon, United Kingdom) as activator and plasma fibrinogen as substrate. Activation and measurement of both control and patient prothrombin in plasma were also carried out using a 2-stage assay with ♂-Phe-Pip-Arg-pNA as substrate, and either ecarin (Sigma and patient prothrombin in plasma were also carried out using a 2-stage assay with ♂-Phe-Pip-Arg-pNA as substrate, and either ecarin (Sigma-Aldrich, St Louis, MO) or Taipan snake venom as activating agents. Briefly, 100 μL of either normal control or patient plasma was mixed to an equal volume of 50 mM Tris-HCl [0.15 M NaCl, 0.1% polyethylene glycol (PEG) 6000, pH 7.50) at 37°C (buffer A), and incubated for 5 minutes at 37°C with either 10 U/mL ecarin alone or 0.5 mg/mL Taipan snake venom in buffer A plus 0.1% bovine serum albumin (BSA); 5 mM CaCl2, and diluted (1:5, vol/vol) synthetic phospholipids (SynthAsil, Hemoliance; Instrumentation Laboratory, Milan, Italy). At the end of incubation 100 μL of the solution was added to 1 mL of a solution containing 50 mM Tris-HCl, 0.15 M NaCl, 0.1% PEG 6000, 5 mM EDTA, pH 8.00, and containing 100 μM ♂-Phe-Pip-Arg-pNA. The formation of p-nitroaniline was followed at 405 nm in a Varian Cary 2200 spectrophotometer (Mulgrave, Australia). Under these conditions the conversion of ecarin to the synthetic substrate hydrolysis was null, whereas that of the Taipan snake venom was negligible, being the formation of p-nitroaniline less than 0.5 nM/min. A reference curve to convert the rate of pNA formation into active thrombin concentration was obtained using purified WT α-thrombin. Plasma levels of protein C (PC) and antithrombin (AT) were measured by chromogenic assays (COAMATIC Protein C and ElecTracker Antithrombin III, Hemoliance, Instrumentation Laboratory). Free protein S was measured by ELISA (Fee Protein S, Chromogenix, Instrumentation Laboratory). The G1691A mutation in the factor V and the G20210A mutation in the prothrombin gene were searched for by specific DNA amplification and digestion, as previously published.16

DNA analysis

Following DNA extraction from leukocytes, the coding region, intron/exon boundaries, and the 5' and 3' untranslated regions (UTRs) of the prothrombin gene were amplified by polymerase chain reaction (PCR) and screened for mutations by single-strand conformation polymorphism (SSCP) analysis.3

Site-directed mutagenesis and construction of expression vectors

Full-length complementary DNA (cDNA) of human prothrombin (including 38 base pairs (bp) of 5'-UTR and 97 bp of 3'-UTR) was obtained by PCR amplification of M13 mp18 (kindly provided by Dr Barbara C. Furie, Harvard Medical School, Boston, MA). The entire cDNA generated by PCR amplification (201 bp) was sequenced before transfection. To clone the product of PCR amplification into the SalI/EcoRI vector, we designed the forward and reverse primers, with SalI and EcoRI restriction sites, respectively (forward: 5'-ACGGCTTCAGACAAGCTCTCTCAGT-GACCCAGGAGCTGACACACTA TGGCGCACGTCCGAG-3' and reverse: 5'-GGAAATCCCGTCGAGGATCTATTTTATTGGGAAACCATGTT TTAGAACAACAAAAAATA-3'). The product of PCR amplification was purified, digested with SalI and EcoRI and ligated into the SalI/EcoRI vector that had been digested with the same enzymes, to make the clone pt7-SalI-FII-WTEcoRI.

To investigate the influence of the Arg67His substitution on prothrombin activity, mutant factor II (FII) His67 was obtained by site-directed mutagenesis of PT7-SalI-FII-WTEcoRI using a commercially available kit (Clontech, Palo Alto, CA). Oligonucleotide (5'-CCGGAATGACCTTCTGTTACACATGGCAAGCAACT-3') spanning nucleotides 1301-1336 of the human FII cDNA were used to introduce a G to A position 1322 (bold letters) coding for His67. This primer was also introduced into the restriction site (underlined), arising from a silent GTG-to-GTA mutation at nucleotide 1319, to facilitate screening for clones carrying the mutation. The cloned insert was sequenced and sequencing confirmed that the mutation had been introduced.

SalI/WTEcoRI and SalI-MT67FI-WTEcoRI fragments were prepared from the corresponding pT7 vectors (pt7-SalI-FII-WTEcoRI and pt7-SalI-MT67-FII-WTEcoRI), and ligated separately into the expression plasmid pED-mtxfl. The resulting plasmids, pED-FII-WT and pED-FII-MT67, are dicistronic messenger RNA mammalian expression vector carrying the WT or MT67 FII cDNAs at the 5' open reading frame and the dihydrofolate reductase (DHFR) gene at the 3' open reading frame.

Cell culture and transfection assays

For transient transfection experiments, African green monkey COS-7 cells (CRl1650; American Type Culture Collection, Manassas, VA) were maintained in Dulbecco modified Eagle medium (DMEM) supplemented with 10% (vol/vol) fetal bovine serum (FBS), 2 mM L-glutamine, 10 mM HEPES, pH 7.2, 100 U/mL penicillin G, 100 μg/mL streptomycin, and 8 μg/mL vitamin K1 (phytomenadione; Abbott Laboratories, North Chicago, IL) in a 5% CO2 atmosphere at 37°C. The DNA of pED-FII-WT or pED-FII-MT67 (30 ng) was transfected by electroporation into 5 × 106 COS-7 cells according to the manufacturer’s instructions. After 72 hours, supernatants and cell lysates were assayed for FII antigen level.

Purification of WT and Arg67His prothrombin

Recombinant human WT and Arg67His mutant prothrombin were isolated from about 100 mL cell supernatant concentrates using an affinity chromatography column containing activated agarose coupled to monoclonal antibody human factor II (FII) lot 103.55 from Enzyme Research (Indianapolis, IN), followed by activation of prothrombin by ecarin and ion-exchange purification by high-performance liquid chromatography (HPLC), as previously described.15 WT and Arg67His were purified and characterized as previously described.15 Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) on 4% to 20% gradient gels showed that both WT and Arg67His thrombins were pure with an apparent molecular weight of 35 kd. The purified enzyme was immediately aliquoted and frozen at −80°C until use. The concentration of recombinant thrombins was measured spectrophotometrically at 280 nm, using an extinction coefficient (0.1%) equal to 1.83.

Activation of purified WT and Arg67His prothrombins by the prothrombinase complex

Initial rates of prothrombin activation by human factor Xa (FXa) both in the presence and absence of factor Va (FVa) were measured by discontinuous gel electrophoresis (PAGE) and Western blotting. The steady-state activation isotherm at 37°C was determined, using a FXa concentration of 30 nM, in the presence of 1 μM PPACK to inhibit thrombin. The data were fitted to a competitive inhibition model, as described previously.13

From www.bloodjournal.org by guest on November 13, 2017. For personal use only.
pro-FRS in FVa interaction, no phospholipid reagent was used in this assay to investigate the direct prothrombin interaction with either FXa or FVa and unequivocally attribute the observed effects to each of these interactions only. Reaction mixtures contained 50 nM of either purified WT or Arg67His prothrombin, 5 nM FVa (American Diagnostica, Instrumentation Laboratory, Milan, Italy), 10 nM FVa (Calbiochem, Inalco, Milan, Italy) in 50 mM Tris-HCl, 0.15 M NaCl, 5 mM CaCl₂, 0.1% PEG 6000, pH 7.50. Reactions were started by the addition of FXa. At various times (5-30 minutes when FXa alone was used; 1-5 minutes when both FXa and FVa were used), 100-μL aliquots of the reaction mixtures were quenched by addition to 0.9 mL 50 mM Tris-HCl, 0.15 M NaCl, 5 mM EDTA, 0.1% PEG 6000, pH 7.50, containing 100 μM d-Phe-Pip-Arg-pNA. Thrombin was used at a concentration of 1 nM.

Michaelis constants pertaining to WT and Arg67His thrombins for synthetic substrate hydrolysis

The kcat and Km values for substrate hydrolysis by WT and Arg67His thrombins were measured as previously detailed, in 10 mM Tris-HCl, 0.15 M NaCl, 0.1% PEG 6000, pH 7.50 at 25°C (buffer A). The synthetic substrate used was d-Phe-Pip-Arg-pNA. Thrombin was used at a concentration of 1 nM.

Binding affinity of thrombin for thrombomodulin and glycoprotein Ibα by solid-phase assay

Human recombinant thrombomodulin (TM) was purchased from American Diagnostica (Greenwich, CT). Soluble glycoprotein Ibα (GpIbα) 1-282 fragment was purified from outdated platelet concentrates, as previously detailed. Binding of thrombin to human TM and purified GpIbα fragment was performed by solid-phase assays, as described. Detection of thrombin was accomplished by incubating each well with 150 μL 100 μM d-Phe-Pip-Arg-pNA in 50 mM Tris, 0.2 M NaCl, 0.1% PEG 6000, pH 8.00, at 25°C. The absorbance was measured at 405 nm using a microplate reader Auto-Reader III system (Ortho Clinical Diagnostics, Milan, Italy). Each determination (sample and blank) was performed in duplicate.

Measurement of kcat/Km for PC activation by WT and Arg67His thrombin forms

Hydrolysis of PC by free WT and Arg67His thrombin forms was monitored using 50 nM α-thrombin, 0.5 μM PC in buffer A at 25°C. At appropriate time intervals the reaction was stopped with 0.3 M HClO4. The solution was then centrifuged at 14 000 rpm and the supernatant aspirated and filtered through 0.22-μm membranes for reversed-phase high-performance liquid chromatography (RP-HPLC) analysis, using a Bio-Rad C18 column (Bio-Rad Laboratories, Hercules, CA). The eluants were 0.1% trifluoroacetic acid (TFA) and 40% acetonitrile in 0.1% TFA. The gradient was from 0% to 100% of acetonitrile in 30 min. The activation peptide was monitored at 205 nm and quantified by a reference curve using the synthetic activation peptide, DTEADQEDQVPDR, purchased from Primm (Milan, Italy). Concentration of the activation peptide at a given time, [AP]p, was fitted to the following equation: [AP]p = [AP]max [1 - exp(-kcat/Km)], where the pseudo first-order rate constant kcat is equal to eKcat/Km (e0 = thrombin concentration), as the data were obtained at PC concentration less than Km of the hydrolytic reaction. When the kcat/Km value was calculated in the presence of TM, the experimental conditions were the same as indicated above, except that the solution contained 100 nM TM, 2 mM CaCl₂ and 10 nM thrombin forms.

Fibrinopeptide release by thrombin

The rate of fibrinogen hydrolysis was studied by monitoring the rate of fibrinopeptide A release at different fibrinogen concentrations ranging from 0.5 to 64 μM, using a RP-HPLC method, previously detailed. WT and Arg67His thrombin forms were used in buffer A at 0.2 and 2 nM concentrations, respectively. The Michaelis parameters for steady-state hydrolysis were calculated by the GRAFIT software (Erithacus Software, Staines, United Kingdom).

Inhibition of WT and Arg67His thrombin forms by AT and heparin cofactor II

Pseudo–first-order kinetics formalism was used to investigate the interaction of WT and Arg67His thrombin forms with 2 serpins, that is, AT and heparin cofactor II (HCII) in the absence of GAG. HCII (American Diagnostica) was incubated at 1 μM concentration with 0.1 μg/mL polybrene (Sigma-Aldrich) in 10 mM Tris-HCl, 0.15 M NaCl, 0.1% PEG 6000, pH 7.50 (buffer A) at 37°C. The reaction was started by adding 50 nM wild-type or Arg67His. At various time points, a 25-μL aliquot was removed and added to a solution containing 100 μM d-Phe-Pip-Arg-pNA in buffer A at 37°C to measure the velocity of amidase activity of the residual thrombin in a thermostatted Varian Cary 2200 spectrophotometer. The amount of residual thrombin present in solution was proportional to the initial velocity of the amidase reaction, following the equation: Vt = V0 exp(-k t/Km), where Vt and V0 are the velocity at time t and zero, respectively, while k is the apparent first-order rate constant of thrombin-HCII interaction. The value of the second-order rate constant, kcat, was calculated by dividing k by the serpin concentration.

For experiments using AT, progress curve kinetics was used to analyze the experimental data. AT was used between 10 and 15 μM in buffer A at 37°C. The reaction with thrombin was started by adding 0.1 nM WT or Arg67His and the release of p-nitroaniline was measured as a function of time at 405 nm. Progress curves for the thrombin-AT complex formation were analyzed by the following relation: Vt = V0 +[(V0 - VN)(1 - exp(-k t)/k′)], where Vt is the concentration of p-nitroaniline at time t, k has the same meaning as the immediately preceding equation, and VN and Vt are the initial and steady-state velocities of substrate hydrolysis, respectively. Progress curves fitted to this equation provided estimates for k′, VN, and Vt. The association second-order rate constant, kcat, for thrombin-AT interaction was calculated by using the relation: kcat = k′(1-Vt/V0)(1+(S/Km(AT)), where S is the Phe-Pip-Arg-pNA concentration and Km is the Michaelis constant of its hydrolysis by thrombin, calculated in separate experiments. The measurements were also performed in duplicate.

Progress curve kinetics was also used to derive the km of both AT and HCII interaction with WT and mutant thrombin in the presence of high-molecular-weight heparin from porcine intestinal mucosa (Sigma-Aldrich; sodium salt grade I-A, 170 USP/mg, average molecular weight, 16 500 d) and porcine dermatan sulfate (Sigma-Aldrich; sodium salt grade I-A, 170 USP/mg, average molecular weight, 30 000 d), respectively. For thrombin-AT interaction an optimal heparin concentration of 75 nM was previously determined and used in functional experiments using 0.15 μM AT, 0.15 nM WT or mutant thrombin, and 100 μM d-Phe-Pip-Arg-pNA as substrate. Preliminary control experiments showed that for thrombin-HCII interaction the optimal dermatan sulfate concentration was 25 μM. Thus for thrombin-HCII interaction, the experiments were carried out using 25 nM HCII, 25 μM dermatan sulfate, 0.2 to 1 nM WT or mutant thrombin.

Measurement of the PAR1 peptide hydrolysis by WT and mutant Arg67His thrombins

Hydrolysis of the protease-activated thrombin receptor-1 (PAR1) peptide (PAR1P, NH2-LDPRSFLLRNPNDKPYPFWDEDE-COOH; single-letter amino acid codes), purchased from Primm (Milan, Italy) by the different thrombin forms was followed by measuring the release of the peptide LDPR, resulting from the cleavage of the NH2-terminus of PAR-1, according to a previously described method. Briefly, 0.5 μM PAR1P peptide was incubated with 50 to 100 pM WT or mutant thrombins (1 nM for the Arg67Ala form) in 10 nM HEPES, 0.15 M NaCl, 0.1% PEG 6000, pH 7.5, at 25°C. At time intervals (1, 2, 3, 4, 8, 12, and 15 minutes) the reaction was stopped with 0.3 M HClO4 and the cleaved peptide was measured by RP-HPLC, using a 250 × 4.6 mm RP-304 column (Bio-Rad), as previously detailed.

Interaction of WT and Arg67His thrombin forms with platelets

We investigated the effect of Arg67His thrombin on the enzyme capacity to activate gel-filtered platelets. The latter were prepared in 10 mM HEPES,
Expression studies

To investigate the function of the mutant proteins, the pED-FII-WT and pED-FII-MT67 vectors were expressed in COS-7 cells by transient transfection. Enzyme immunoassay of the cell lysates and conditioned media demonstrated that the prothrombin antigen level conditioned media of the WT and Arg67His mutant, respectively. R is the gas constant and T the absolute temperature.

Results

Coagulation and genomic studies

Coagulation assays repeated in Italy in the patient’s fresh-frozen plasma confirmed a marked prolongation of both the prothrombin time and the activated partial thromboplastin time and severe prothrombin deficiency as measured by a classical coagulant assay (<1%) contrasting with almost normal levels of prothrombin as antigen (61% ± 7%) and active enzyme (66% ± 8%) as measured by a 2-stage ecarin assay. On the other hand, the prothrombin concentration measured by the Taipan venom amidolytic assay was lower than the control, being 44% ± 5%. The dissociation between these results suggested the presence of a dysfunctional molecule and prompted us to study the activation of purified prothrombin by the prothrombinase complex, as reported below. A thrombophilic condition was ruled out in the patient, who had AT (115%), PC (71%), and free protein S (70%) levels within the normal range. The patient had neither G20210A mutation in the prothrombin gene nor the G1691A mutation in the factor V gene.

Expression studies

To determine the molecular abnormality associated with the deficiency, the entire coding region and 5’-3’UTR of the prothrombin gene were amplified and screened by SSCP analysis. An abnormally migrating fragment was detected in exon 10. Sequence analysis revealed the patient to be homozygous for a nucleotide substitution that resulted in the Arg67His substitution. Both the parents were heterozygous for the same substitution.

Enzymatic activity of the mutant Arg67His thrombin toward synthetic and natural substrates

The Michaelis parameters pertaining to the hydrolysis of the synthetic substrate Phe-Pip-Arg-pNA are given in Table 1. The Arg67His mutation did not significantly alter the amidase activity of thrombin, suggesting that this substitution does not affect the interaction of the substrate with S1-S4 of the enzyme. By contrast, the interaction of thrombin with natural substrates, such as fibrinogen and thrombin receptor (TR), showed profound changes compared to WT. In fact, fibrinopeptide A hydrolysis was characterized by an approximate 13-fold increase of the K_m value (38 μM vs 3 μM) and by a 2-fold decrease of the kcat value (32.5 s⁻¹ vs 64 s⁻¹), as shown in Figure 1A. Thus, the kcat/K_m value decreased from 2.1 x 10⁻⁷ M⁻¹s⁻¹ to 9 x 10⁻⁸ M⁻¹s⁻¹, that is, 22-fold, as shown in Table 1. This finding may explain the loss of the clotting capacity of the mutant thrombin in patient plasma.

Hydrolysis of PC in the absence of TM was not affected by the mutation, because the kcat/K_m value was very close to that observed with the WT enzyme, as shown in Table 1. This finding is in substantial agreement with previous data, showing that thrombin does not involve its FRS in its interaction with free PC, except when the enzyme forms a ternary complex with TM and PC, as shown in experiments using TM as cofactor (see below).

Interaction of the mutant Arg67His thrombin with TM

Solid-phase binding experiments showed that Arg67 plays a central role in the interaction with TM, because the K_d decreased 33-fold in the Arg67His mutant, as shown in Figure 2A. The defective binding of the mutant thrombin severely affected the catalytic competence of the enzyme in PC hydrolysis. Under experimental conditions, the kcat/K_m value decreased from 4 x 10⁻⁷ M⁻¹s⁻¹ to 1.2 x 10⁻⁶ M⁻¹s⁻¹, that is, 32-fold (Table 1).

Hydrolysis of the PAR-1 38-60 peptide by WT (●) and Arg67His mutant (○) thrombin. Continuous lines were drawn according to the best-fit kcat and K_m values listed in Table 1. The SE is expressed by the vertical bars.

Table 1. Enzymatic properties of the Arg67His mutant thrombin toward synthetic and natural substrates/ligands

<table>
<thead>
<tr>
<th>Substrate</th>
<th>Kcat (s⁻¹)</th>
<th>K_m (μM)</th>
<th>kcat (s⁻¹)</th>
<th>K_m (μM)</th>
<th>∆ΔG° (Kcal/mol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phe-Pip-Arg-pNA</td>
<td>85 ± 9</td>
<td>2.1 ± 0.2</td>
<td>81 ± 8</td>
<td>2.0 ± 0.1</td>
<td>0</td>
</tr>
<tr>
<td>Fibrinogen (Au)</td>
<td>64.3 ± 1.3</td>
<td>2.9 ± 0.2</td>
<td>32.5 ± 2.9</td>
<td>37.8 ± 6.5</td>
<td>1.9</td>
</tr>
<tr>
<td>TR 38-60 peptide</td>
<td>106 ± 2.3</td>
<td>2.7 ± 0.2</td>
<td>49.9 ± 3.2</td>
<td>62.2 ± 8.3</td>
<td>2.6</td>
</tr>
<tr>
<td>PC (no TM)</td>
<td>5.03 ± 0.4 x 10³</td>
<td>4.7 ± 0.2 x 10³</td>
<td>3.7 x 10⁷</td>
<td>1.1</td>
<td></td>
</tr>
<tr>
<td>PC (with 100 nM TM)</td>
<td>2.3 x 10⁸</td>
<td>3.4 x 10⁸</td>
<td>1.1 x 10⁹</td>
<td>0.4</td>
<td></td>
</tr>
</tbody>
</table>

* ∆ΔG° is the difference in free energy of activation for substrate hydrolysis, calculated as RT ln (R_m/R_W) where R_m and R_W are the kcat/K_m pertaining to substrate hydrolysis by WT and Arg67His mutant, respectively. R is the gas constant and T the absolute temperature.
conditions using 100 nM TM and either 10 nM WT or mutant thrombin, the apparent $k_{on}/K_m$ value pertaining to PC hydrolysis decreased from $2.3 \times 10^5$ M$^{-1}$ s$^{-1}$ to $3.7 \times 10^3$ M$^{-1}$ s$^{-1}$ as shown in Figure 2B. This inhibitory effect was attributed to a defective TM interaction, because PC hydrolysis by the Arg67His mutant enzyme, as reported above, was unchanged compared to the wild-type form.

**Interaction of WT and Arg67His thrombin with AT and HCII**

The best-fit second-order rate constants for both WT and Arg67His interaction with AT and HCII in the presence and absence of heparin and dermatan sulfate, respectively, are listed in Table 3. HClI interaction with Arg67His thrombin decreased roughly 3-fold compared to WT, in the absence of dermatan sulfate. This result was in agreement with previous findings that the N terminus of HClI interacts with the thrombin FRS. This defect was even more evident in the presence of dermatan sulfate, where Arg67His showed a 500-fold decrease of its $k_{on}$ value compared to WT thrombin. On the contrary, the Arg67His interaction with AT did not show such drastic decrease both in the absence and presence of heparin. This finding is in agreement with previous findings that FRS is not engaged in thrombin interaction with this serpin.

**Interaction of WT and mutant Arg67His thrombin with gel-filtered platelets**

The Arg67His mutant thrombin showed a defect in its capacity to activate gel-filtered platelets, the EC$_{50}$ value being increased 10-fold compared to WT (Figure 3). This biologic effect was attributed to a defective PAR-1 interaction only, because solid-phase binding experiments showed a normal interaction with GpIb, the other major thrombin receptor involved in the activation of human platelets. The $K_d$ value of this binding was equal to 109 ± 12 nM in WT and 123 ± 18 nM in Arg67His. This finding is in agreement with recent data showing that a similar but not isosteric and isoelectric mutation at Arg67, that is Arg67Ala, does not affect thrombin interaction with GpIb.

**Activation of purified WT and Arg67His prothrombin with the FXa-FVa complex**

The Arg67His mutation caused a net decrease of the initial rates of prothrombin activation by FXa only when FVa was present in the activation mixture. When FXa alone was used at concentrations of 10 nM in the activation mixture, the initial rates of prothrombin activation were 6.5 ± 0.9 pM/min and 5.7 ± 0.1 pM/min for WT and Arg67His prothrombin, respectively (Table 4). By contrast, when 10 nM FXa plus 5 nM FVa was used, the initial rates of prothrombin activation were 500 ± 90 pM/min and 100 ± 15 pM/min for WT and Arg67His, respectively (Table 4). These experiments showed that Arg67His mutation reduced the cofactor effect of FVa in the FXa-catalyzed prothrombin activation.

**Discussion**

In a recent study aimed at screening natural variants of prothrombin in a large cohort of families, we identified and investigated a woman with undetectable plasma levels of prothrombin activity, borderline levels of prothrombin antigen, and a very mild bleeding diathesis. The latter finding is in contrast with what we found in other patients with hyperprothrombinemia, who usually suffer from more severe spontaneous and posttraumatic bleeding symptoms, despite the fact that, at variance with our patient, they have measurable levels of prothrombin activity. A homozygous Arg67His mutation in the prothrombin gene, which results in the loss of a positive charge within the FRS of thrombin, was found. The amino acid substitution involves an arginine and can be hypothesized to alter the enzyme interaction with natural substrates and modulators that bind to FRS, such as fibrinogen, PAR-1, or thrombomodulin. The positively charged FRS residues contribute significantly to
enhance the rate of complex formation with thrombin ligands through steering with complementary electrostatic fields and a coordinated combination of molecular contacts within the complex that is peculiar for each macromolecular ligand.

A severe reduction of the catalytic competence of thrombin toward the fibrinogen Aa-chain was observed for the Arg67His mutant. Among the congenitally dysfunctional forms of prothrombin, 2 other compound heterozygous forms, Quick I and Corpus Christi, were found to bear a mutation at Arg67 and to have a reduced interaction with fibrinogen. Both these variants have a cysteine residue at position 67, besides a Gly→Val mutation at residue 226 and a stop codon at the site of Gln209, which may be gous forms, especially in mutants bearing a Gly mutation at Arg67. The defective enzymatic activity could be attributed also to the molecular recognition of prothrombin by the complex, possibly by direct involvement of pro-FRS in FVa binding. The 5-fold reduction of the initial rate of the Arg67His prothrombin activation by FXa only in the presence of FVa corroborates the recently proposed role, direct or allosteric, of the pro-FRS domain in prothrombin interaction with FVa. The present findings would suggest that Arg67 participates indeed in this interaction. It is also of interest that activation of the mutant Arg67His prothrombin by the Taipan snake venom gave a value of plasma prothrombin concentration lower than that obtained with the ecarin assay. These snake venoms belong to different classes of prothrombin activators. Ecarin converts prothrombin into meizothrombin, which autocatalytically produces active thrombin, in absence of FVα or phospholipids. By contrast, Taipan snake venom needs Ca²⁺ and phospholipids to activate thrombin, being associated with a FVα-like cofactor activity. The Arg67His mutation could thus inhibit the FVα-like activity of this venom. These findings suggest also that the initial characterization of prothrombin variants should include the use of different classes of venom activators to disclose dysfunctional features of the variants.

Despite the major functional defects discussed above, the Arg67His mutant was associated with very mild bleeding symptoms. This prompted us to investigate other thrombin interactions with modulators and natural inhibitors involved in the regulation of the anticoagulant functions as well as in the inhibition of the enzyme. TM is an integral glycoprotein of the endothelial cell membrane and binds to thrombin, switching the function of this enzyme from procoagulant to anticoagulant through the activation of the PC pathway. Previous nuclear magnetic resonance (NMR) and x-ray diffraction studies showed that the endothelial growth factor (EGF) 5-6 domains of TM make many hydrogen and salt bridges with FRS thrombin residues. Arg67 is involved in this bond network because the hydroxyl group of TM Tyr413 makes a hydrogen bond with the guanidyl side chain of thrombin Arg67. In our experiments the Arg67His variant showed a reduced interaction with TM, expressed by a K_d value 5-fold higher than in the WT form. This defect caused a defective TM-catalyzed PC hydrolysis. The activation of PC alone, in the absence of TM, did not undergo a reduction of the apparent k_cat/K_m value, as reported in Table 1. On the other hand, in the presence of a high TM concentration, the apparent k_cat/K_m value was 6-fold lower for the Arg67His mutant than for the WT. It may be thus hypothesized that in vivo the TM-linked physiologic formation of activated PC undergoes a drastic impairment. Thus, the most relevant TM-linked anticoagulant function of thrombin was as defective as that pertaining to the clotting capacity of the enzyme. This anticoagulant dysfunction might in part counterbalance the procoagulant defect of the mutant, leading to surmise that the formation of active thrombin in the patient is not down-regulated by activated PC. This may help explain the very mild bleeding tendency of the patient carrying this natural variant.

The study of HCII and AT interaction with the Arg67His mutant might further unravel the apparent enigma of the absence of a severe hemorrhagic syndrome in the patient. Kinetic experiments showed for the Arg67His mutant a strong decrease of the second-order rate constant of HCII association both in the absence (3-fold) and especially in the presence of dermatan sulfate (500-fold). In addition, a moderate decrease of the AT association rate constant in the presence of heparin (1.5-fold) was observed. The severely defective interaction of the mutant thrombin with HCII is in agreement with the involvement of the N-terminus of HCII in the ligation of thrombin FRS. The HCII inhibitory activity toward thrombin is strongly enhanced by the presence of glycosaminoglycans (GAGs), such as dermatan sulfate, which allosterically “activates” HCII. A specific dermatan sulfate hexasaccharide sequence composed of repeats of iduronic acid 2-sulfate and N-acetylgalactosamine 4-sulfate has been shown to bind to a cationic domain of HCII. This binding disrupts the intramolecular

Table 4. Initial rates of 50 nM WT and Arg67His prothrombin activation by either 10 nM FXα alone or a combination of 10 nM FXα plus 5 nM FVa

<table>
<thead>
<tr>
<th>Activating agent</th>
<th>WT-FII v_max (pM/min)</th>
<th>Arg67His-FII v_max (pM/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FXα</td>
<td>6.5 ± 0.9</td>
<td>5.7 ± 0.1</td>
</tr>
<tr>
<td>FXα + FVa</td>
<td>500 ± 90</td>
<td>100 ± 15</td>
</tr>
</tbody>
</table>

Results are based on the experimental conditions reported in text. *The values of mean ± SD from 2 different measurements are reported.
docking, allowing the free N-terminal acidic domain of the inhibitor to bind to the FRS of thrombin. Given the selectivity with which dermatan sulfate activates HCII among all serpins interacting with GAGs, and the presence of dermatan sulfate in the extracellular matrix of a wide variety of tissues, HCII has been proposed to inhibit "extravascular" thrombin activity. This inhibitory mechanism has been proposed to oppose the procoagathogenic activity of thrombin.

In our patient, the impaired thrombin-HCII interaction might oppose the defective procoagulant capacity of the thrombin mutant, increasing the half-life of free thrombin. The interaction of Arg67Ala thrombin with AT showed only a modest reduction, consistent with the fact that the thrombin-AT interaction does not involve directly the FRS. The modest reduction of the association rate of the interaction in the presence of heparin might further contribute to a reduced inhibition in vivo of the thrombin variant.

In conclusion, the experimental data showed that both procoagulant and anticoagulant functions of the Arg67His mutant are impaired. Moreover, the mutation induced a strongly defective inhibition of thrombin by HCII. Altogether, these functional abnormalities might somewhat counterbalance each other so that ultimately the hemostatic equilibrium does not undergo drastic changes, explaining the very mild clinical phenotype associated with this congenital type II prothrombin deficiency.

References

Molecular and functional characterization of a natural homozygous Arg67His mutation in the prothrombin gene of a patient with a severe procoagulant defect contrasting with a mild hemorrhagic phenotype

Sepideh Akhavan, Raimondo De Cristofaro, Flora Peyvandi, Silvia Lavoretano, Raffaele Landolfi and Pier M. Mannucci